OMER - Omeros Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
18.08
-1.52 (-7.76%)
At close: 4:00PM EST

18.08 0.00 (0.00%)
After hours: 4:29PM EST

Stock chart is not supported by your current browser
Previous Close19.60
Open19.57
Bid18.15 x 100
Ask18.45 x 200
Day's Range18.04 - 19.88
52 Week Range8.71 - 27.09
Volume996,429
Avg. Volume906,103
Market Cap867.909M
Beta3.61
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Omeros Scores Relative Strength Rating Upgrade; Hits Key Threshold
    Investor's Business Daily6 days ago

    Omeros Scores Relative Strength Rating Upgrade; Hits Key Threshold

    Omeros shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 85.

  • This Is Why Omeros Jumped 95.8% in 2017
    Motley Fool6 days ago

    This Is Why Omeros Jumped 95.8% in 2017

    Rising sales and upbeat clinical news have left investors feeling optimistic.

  • Omeros Inks Agreement With FDA for OMS721 Phase III Trial
    Zacks12 days ago

    Omeros Inks Agreement With FDA for OMS721 Phase III Trial

    Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.

  • At $20.155, Is Omeros Corporation (NASDAQ:OMER) A Buy?
    Simply Wall St.13 days ago

    At $20.155, Is Omeros Corporation (NASDAQ:OMER) A Buy?

    Omeros Corporation (NASDAQ:OMER), a pharmaceuticals company based in United States, saw a significant share price rise of over 20% in the past couple of months on the NasdaqGM. With manyRead More...

  • SmarterAnalyst13 days ago

    Omeros Corporation (OMER) Provides Regulatory Update on OMS721; Shares Soar 8%

    This morning, the drug maker announced that it has reached an agreement with the FDA that available data from OMS721 supports the prospect for benefit in IgA nephropathy (IgAN) patients. Following the approval of the Phase 3 trial protocol, patient enrollment is expected to begin early next month. Omeros CEO Gregory Demopulos commented, "We’re pleased to have received agreement from FDA for our OMS721 Phase 3 protocol in IgA nephropathy [...] Final preparations to begin the trial can now be completed and enrollment is expected to open in early February.

  • Capital Cube21 days ago

    ETFs with exposure to Omeros Corp. : December 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Omeros Corp. Here are 5 ETFs with the largest exposure to OMER-US. Comparing the performance and risk of Omeros Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Omeros Corp. :OMER-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
    Capital Cube22 days ago

    Omeros Corp. :OMER-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017

    Categories: Yahoo FinanceGet free summary analysis Omeros Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Omeros Corp. – Pfizer Inc., BioTime, Inc., Acura Pharmaceuticals, Inc., Akorn, Inc., DURECT Corporation and Pain Therapeutics, Inc. (PFE-US, BTX-US, ACUR-US, AKRX-US, DRRX-US and PTIE-US) that have also reported ... Read more (Read more...)

  • Can Omeros (OMER) Run Higher on Strong Earnings Estimate Revisions?
    Zacks26 days ago

    Can Omeros (OMER) Run Higher on Strong Earnings Estimate Revisions?

    Omeros (OMER) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

  • Here's Why Omeros Corporation Is Gaining More Ground Today
    Motley Foollast month

    Here's Why Omeros Corporation Is Gaining More Ground Today

    Pediatric exclusivity is a bigger deal than you might expect for a drug used during cataract surgeries.

  • Benzingalast month

    Omeros' OMIDRIA Eye Drop OK'ed For Pediatric Use

    Omeros Corporation (NASDAQ: OMER ) shares are trading higher Tuesday after the commercial-stage biopharma company announced FDA approval for its supplemental new drug application, or sNDA, for OMIDRIA, ...

  • Omeros Earns Relative Strength Rating Upgrade
    Investor's Business Daily2 months ago

    Omeros Earns Relative Strength Rating Upgrade

    Omeros sees its Relative Strength Rating enter the elite 90-plus level.

  • Why Omeros Corporation Is the Best Buy in Biotech Right Now
    Motley Fool2 months ago

    Why Omeros Corporation Is the Best Buy in Biotech Right Now

    This overlooked small-cap biotech stock has two well-lit paths to glory, but you only need to pay for one.

  • Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : November 27, 2017
    Capital Cube2 months ago

    Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : November 27, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Omeros Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of OMER earnings conference call or presentation 9-Nov-17 9:30pm GMT

    Q3 2017 Omeros Corp Earnings Call

  • Capital Cube2 months ago

    Omeros Corp. – Value Analysis (NASDAQ:OMER) : November 17, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Omeros Corp. a score of 36. Our analysis is based on comparing Omeros Corp. with the following peers – Genetic Technologies Limited Sponsored ADR, BioTime, Inc., Acura Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., DURECT Corporation, Akorn, Inc. and Pain Therapeutics, Inc. (GENE-US, BTX-US, ACUR-US, JNJ-US, PFE-US, ... Read more (Read more...)

  • Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : November 16, 2017
    Capital Cube2 months ago

    Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : November 16, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Omeros Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • TheStreet.com2 months ago

    5 Small Biotechs Receive Shots in the Arm

    Favorable quarterly results and FDA drug approvals should help lift these five names.

  • This Biotech Just Rose By A Third On Its Earnings — But Is It In Trouble?
    Investor's Business Daily2 months ago

    This Biotech Just Rose By A Third On Its Earnings — But Is It In Trouble?

    Omeros rocketed to a month-high Friday after revenue from eye-surgery drug Omidria beat its typical summertime weakness.

  • SmarterAnalyst2 months ago

    Omeros Story Continues to Get Better, but Reimbursement Risk Remains

    The fundamentals behind Omeros' (NASDAQ:OMER) eye drug Omidria continue to get better, but Cantor analyst Elemer Piros believes the company still needs to remove the uncertainty around the expiration of pass-through reimbursement.

  • This Is Why Omeros Corporation Shares Are Rocketing 33% Higher Today
    Motley Fool2 months ago

    This Is Why Omeros Corporation Shares Are Rocketing 33% Higher Today

    This company took important steps forward last quarter to continue growing.

  • Benzinga2 months ago

    Can Omeros Top-Line Growth Continue?

    Omeros Corporation (NASDAQ: OMER ) shares are on a tear, the catalyst being the release of its third-quarter results. The Analyst Cantor Fitzgerald's Elemer Piros, Ph.D, reviewed Omeros' quarterly results. ...

  • MarketWatch2 months ago

    Omeros shares surge 17% after Q3 revenue beat

    Omeros Corp. shares rose 17% in premarket trade Friday after the company reported a third-quarter revenue beat and a narrower-than-expected profit loss. The company reported a loss of $7.48 million, or ...

  • SmarterAnalyst2 months ago

    Omeros Corporation (OMER) Shares Soar Following Strong Quarter

    Omeros Corporation (NASDAQ:OMER) shares are on fire this evening, rising nearly 11%, after the drug maker reported better-than-expected 3Q Omidria sales. 3Q 2017 total and OMIDRIA® revenues were $21.7 million. Revenues from OMIDRIA sales rose 26 percent from 2Q 2017 and 92 percent from the prior year’s third quarter.

  • Associated Press2 months ago

    Omeros reports 3Q loss

    On a per-share basis, the Seattle-based company said it had a loss of 16 cents. Losses, adjusted for non-recurring costs, came to 7 cents per share. The drug developer posted revenue of $21.7 million in ...

  • Omeros Corporation (OMER): Extended Follow-Up Data Evaluating OMS721 Shows Improvement in Patients with IgA
    SmarterAnalyst2 months ago

    Omeros Corporation (OMER): Extended Follow-Up Data Evaluating OMS721 Shows Improvement in Patients with IgA

    Omeros Corporation (NASDAQ:OMER) announced that extended follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 were presented on November 4, 2017 at the American Society of Nephrology (ASN) Meetingin New Orleans. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. During the Phase 2 clinical trial, which consisted of 12 weeks of treatment and 6 weeks of follow-up, all patients with IgA nephropathy demonstrated clinically meaningful improvement in proteinuria.